MAPK3, mitogen-activated protein kinase 3, 5595

N. diseases: 647; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 AlteredExpression disease BEFREE With this premise, this study examined in HeLa and other cell lines the effects of different APDs on the activation of ERK1/2 (Extracellular signal-regulated kinases) and AKT (Protein Kinase B) kinases, which may be affected in schizophrenia and bipolar disorder. 28283227 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Network analysis identified MAPK3, which encodes ERK1 MAP kinase, as the most topologically important hub in protein-protein interaction networks within the 16p11.2 region and broader gene networks of schizophrenia-associated CNVs. 27402753 2016
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET Both single-gene and gene-set enrichment analyses in genome-wide association data from the largest schizophrenia sample to date of 13,689 cases and 18,226 controls show significant association of HIST1H1E and MAPK3, and enrichment of our PSD proteome. 25048004 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Both single-gene and gene-set enrichment analyses in genome-wide association data from the largest schizophrenia sample to date of 13,689 cases and 18,226 controls show significant association of HIST1H1E and MAPK3, and enrichment of our PSD proteome. 25048004 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: basal contents and effects of psychotropic treatments. 25075716 2014
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET Given the role of ERK1/2, alphaCaMKII and CREB in neuroplastic mechanisms and cell communication, our data suggest that their decreased activation following chronic PCP administration can contribute to cortical defects occurring in schizophrenia, and may therefore represent potential targets for pharmacological intervention. 18406625 2008